Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Rhenium-186 rhenium

Synonyms: AC1L4OT7, 186Re, Rhenium, isotope of mass 186

Israel, O. et al., Colnot, D.R. et al., Manil, L. et al., O'Sullivan, J.M. et al., Marchal, J.C. et al., et al.

O'Sullivan, McCready, Flux, Norman, Buffa, Chittenden, Guy, Pomeroy, Cook, Gadd, Treleaven, Al-Deen, Horwich, Huddart, Dearnaley, Marchal, Klein, Thouvenot, Bernier, Moret, Chastagner, Israel, Keidar, Rubinov, Iosilevski, Frenkel, Kuten, Betman, Kolodny, Yarnitsky, Front, Hamby, Chinol, Palestro, Manzo, Ferrone,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of rhenium

PURPOSE: To calculate radiation doses of rhenium-186 ((186)Re) etidronate in painful bone metastases using quantitative bone single-photon emission computed tomography (SPECT) and to determine the threshold dose for predicting pain relief [1].
Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate [1].
PURPOSE: In an earlier Phase I radioimmunotherapy (RIT) study with rhenium-186-labeled chimeric monoclonal antibody (cMAb) U36 in patients with refractory head and neck squamous cell carcinoma, the maximum tolerated activity was established at 1.0 GBq/m2, at which bone marrow doses ranged from 0.7 to 1.1 Gy [2].
Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody [3].
Rhenium-186 based radioimmunotherapy (RIT) may have potential for the treatment of minimal residual disease in patients with squamous cell carcinoma of head and neck (HNSCC) [4].

High impact information on rhenium

Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23 [5].
Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody [6].
Rhenium-186 (tin) hydroxyethylidene diphosphonate (HEDP) is a new radiopharmaceutical that simultaneously localizes in multiple skeletal metastases in patients with advanced cancer [7].
Administered activities of 5000 MBq of Rhenium-186 hydroxyethylidene diphosphonate are feasible using autologous peripheral blood peripheral blood stem cell rescue in patients with progressive hormone refractory prostate cancer metastatic to bone [8].
Better results with rhenium-186 radiosynoviorthesis than with cortivazol in rheumatoid arthritis (RA): a two-year follow-up randomized controlled multicentre study [9].

Chemical compound and disease context of rhenium

Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases [10].
In this case report we demonstrate the usefulness of targeted radiotherapy in the form of rhenium-186 HEDP as a method for dose escalation in the treatment of osteosarcoma [11].
The use of Strontium-89 in the treatment of other bone neoplasms and the use of other radionuclides, such as Rhenium-186 HEDP and Samarium-153 EDT-MP, are still investigational [12].

Anatomical context of rhenium

For rhenium-186 (both beta and gamma emitter), whole body scans and static images of joints and locoregional lymph nodes were performed [13].
Rhenium-186 leak is greater, as demonstrated by the higher blood activity and the measurable, although limited, dicentrics induction in blood lymphocytes [13].

Associations of rhenium with other chemical compounds

Several polyamine ligands L1-L7 were assessed as chelators for rhenium-188 (and by analogy, rhenium-186) for incorporation into the design of radiopharmaceuticals for targeted radiotherapy [14].

Analytical, diagnostic and therapeutic context of rhenium

In this perspective they focus on other therapeutic methods: endocavity treatment of cysts with rhenium-186, triconformational radiotherapy, radiosurgery, and widespread use of the trans-sphenoidal approach [15].

References

Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. Israel, O., Keidar, Z., Rubinov, R., Iosilevski, G., Frenkel, A., Kuten, A., Betman, L., Kolodny, G.M., Yarnitsky, D., Front, D. J. Clin. Oncol. (2000) [Pubmed]
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Colnot, D.R., Ossenkoppele, G.J., Roos, J.C., Quak, J.J., de Bree, R., Börjesson, P.K., Huijgens, P.C., Snow, G.B., van Dongen, G.A. Clin. Cancer Res. (2002) [Pubmed]
Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. Breitz, H.B., Fisher, D.R., Wessels, B.W. J. Nucl. Med. (1998) [Pubmed]
Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. van Gog, F.B., Brakenhoff, R.H., Stigter-van Walsum, M., Snow, G.B., van Dongen, G.A. Int. J. Cancer (1998) [Pubmed]
Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23. Hamby, C.V., Chinol, M., Palestro, C.J., Manzo, C., Ferrone, S. Int. J. Cancer (1998) [Pubmed]
Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody. Breitz, H.B., Durham, J.S., Fisher, D.R., Weiden, P.L., DeNardo, G.L., Goodgold, H.M., Nelp, W.B. J. Nucl. Med. (1995) [Pubmed]
Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. Maxon, H.R., Schroder, L.E., Hertzberg, V.S., Thomas, S.R., Englaro, E.E., Samaratunga, R., Smith, H., Moulton, J.S., Williams, C.C., Ehrhardt, G.J. J. Nucl. Med. (1991) [Pubmed]
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. O'Sullivan, J.M., McCready, V.R., Flux, G., Norman, A.R., Buffa, F.M., Chittenden, S., Guy, M., Pomeroy, K., Cook, G., Gadd, J., Treleaven, J., Al-Deen, A., Horwich, A., Huddart, R.A., Dearnaley, D.P. Br. J. Cancer (2002) [Pubmed]
Better results with rhenium-186 radiosynoviorthesis than with cortivazol in rheumatoid arthritis (RA): a two-year follow-up randomized controlled multicentre study. Tebib, J.G., Manil, L.M., Mödder, G., Verrier, P., De Rycke, Y., Bonmartin, A., Devaux, J.Y., Chossat, F., Menkes, C.J., Kahan, A. Clinical and experimental rheumatology. (2004) [Pubmed]
Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. de Klerk, J.M., van Dijk, A., van het Schip, A.D., Zonnenberg, B.A., van Rijk, P.P. J. Nucl. Med. (1992) [Pubmed]
Rhenium-186 HEDP as a boost to external beam irradiation in osteosarcoma. Sawyer, E.J., Cassoni, A.M., Waddington, W., Bomanji, J.B., Briggs, T.W. The British journal of radiology. (1999) [Pubmed]
Systemic radionuclide therapy of bone metastases with strontium-89. Porter, A.T., Davis, L.P. Oncology (Williston Park, N.Y.) (1994) [Pubmed]
Physical and biological dosimetry in patients undergoing radiosynoviorthesis with erbium-169 and rhenium-186. Manil, L., Voisin, P., Aubert, B., Guerreau, D., Verrier, P., Lebègue, L., Wargnies, J.P., Di Paola, M., Barbier, Y., Chossat, F., Menkes, C.J., Tébib, J., Devaux, J.Y., Kahan, A. Nuclear medicine communications. (2001) [Pubmed]
Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use. Prakash, S., Went, M.J., Blower, P.J. Nucl. Med. Biol. (1996) [Pubmed]
Individualized treatment of craniopharyngioma in children: ways and means. Marchal, J.C., Klein, O., Thouvenot, P., Bernier, V., Moret, C., Chastagner, P. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. (2005) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.